We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
-17.14%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$292M
AUM Growth
-$175M
Cap. Flow
-$75.7M
Cap. Flow %
-25.91%
Top 10 Hldgs %
98.38%
Holding
18
New
1
Increased
–
Reduced
1
Closed
3

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
PSNL icon
Personalis
PSNL
+$96.7M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$21.7M
3
TARA icon
Protara Therapeutics
TARA
+$344K
4
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$75.2K

Sector Composition

Rank Sector Weight
1 Healthcare 85.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1
Vaxcyte
PCVX
$8.01B
$111M 37.88%
4,168,718
– –
PHAT icon
2
Phathom Pharmaceuticals
PHAT
$849M
$40M 13.67%
1,203,135
– –
SLNO
3
DELISTED
Soleno Therapeutics
SLNO
$19.9M 6.8%
686,840
– –
VRNA
4
DELISTED
Verona Pharma
VRNA
$16.9M 5.79%
2,457,499
– –
NCNA
5
NuCana
NCNA
$5.45M
$15M 5.12%
667
– –
SRRA
6
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$13.9M 4.76%
871,125
-5,416
-0.6% -$75.2K
XCUR icon
7
Exicure
XCUR
$12M
$12.3M 4.22%
46,513
– –
SIEN
8
DELISTED
Sientra, Inc.
SIEN
$9.3M 3.18%
239,084
– –
PRTK
9
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$6.52M 2.23%
1,041,131
– –
SYRE icon
10
Spyre Therapeutics
SYRE
$8.45B
$1.89M 0.65%
9,620
– –
MTEM
11
DELISTED
Molecular Templates, Inc.
MTEM
$1.88M 0.64%
13,333
– –
CBAY
12
DELISTED
Cymabay Therapeutics
CBAY
$752K 0.26%
131,036
– –
OBSV
13
DELISTED
ObsEva SA Ordinary Shares
OBSV
$182K 0.06%
87,999
– –
OCGN icon
14
Ocugen
OCGN
$450M
$13K ﹤0.01%
7,111
– –
CRSP icon
15
CRISPR Therapeutics
CRSP
$4.74B
– –
-259,599
Closed -$21.7M
PSNL icon
16
Personalis
PSNL
$1.4B
– –
-4,462,452
Closed -$96.7M
TARA icon
17
Protara Therapeutics
TARA
$229M
– –
-20,610
Closed -$344K

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q4 2020 Portfolio in Review

As of Q4 2020, Abingworth held 18 positions worth $292M, down 37% from $468M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Abingworth withdrew a net $75.7M in Q4 2020, closing 3 positions and reducing 1 holding. Its most notable exit was Personalis, an estimated $96.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 100% a quarter earlier.

  • Abingworth's biggest Q4 2020 reduction was Sierra Oncology, Inc. Common Stock, cutting an estimated $75.2K.
  • Abingworth fully exited Personalis in Q4 2020, selling an estimated $96.7M.
  • Abingworth's ten largest holdings make up 98% of its $292M portfolio in Q4 2020.
  • Abingworth opened 1 new position and closed 3 in Q4 2020.
  • Abingworth's portfolio value fell 37% quarter-over-quarter to $292M.

Based on Abingworth's 13F filing for Q4 2020, filed 1 Mar 2021.